Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot studyFilip Van den Bosch, Eric Veys|Annals of the Rheumatic Diseases|2000Cited by 292
A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritisJasper J. Haringman, Paul P. Tak, Tom Smeets et al.|Arthritis & Rheumatism|2006Cited by 255